《Sciencedaily,2月17日,Study strengthens case that vitamins cannot treat COVID-19》

  • 来源专题:COVID-19科研动态监测
  • 编译者: YUTING
  • 发布时间:2022-03-02
  • A new review of COVID-19 hospitalization data by researchers at The University of Toledo has found that taking immune-boosting supplements such as vitamin C , vitamin D and zinc do not lessen your chance of dying from COVID-19.

    Early in the pandemic, healthcare providers tried a variety of micronutrients as potential therapies for the new illness. More recently, supplements have been promoted by some as an alternative to the safe and proven vaccines.

    However, Dr. Azizullah Beran said there's been little evidence those strategies work, despite the enduring interest in them.

    "A lot of people have this misconception that if you load up on zinc, vitamin D or vitamin C, it can help the clinical outcome of COVID-19," said Beran, an internal medicine resident at The University of Toledo College of Medicine and Life Sciences. "That hasn't been shown to be true."

    Beran is the lead author on a new paper that significantly strengthens the emerging medical consensus that micronutrient supplements are not an effective treatment for COVID-19.

    He and his collaborators reviewed 26 peer-reviewed studies from around the globe that included more than 5,600 hospitalized COVID-19 patients. Their analysis found no reduction in mortality for those being treated with vitamin D, vitamin C or zinc compared to patients who did not receive one of those three supplements.

    Their analysis did find that treatment with vitamin D may be associated with lower rates of intubation and shorter hospital stays, but the researchers say more rigorous study is needed to validate that finding.

    Vitamin C and zinc were not associated with shorter hospital stays or lowering the chance a patient would be put on a ventilator.

    While the study predominately looked at patients who were already sick and hospitalized with COVID-19 when given the supplements, researchers did analyze a smaller subset of individuals who had been taking vitamin D prior to contracting the virus. They found no significant difference in the mortality rate of that population either.

    The paper is published in the journal Clinical Nutrition ESPEN.

    "It's important for people to understand that taking a lot of these supplements does not translate into better outcomes," said Dr. Ragheb Assaly, a UToledo professor of medicine and the paper's senior author. "The other important message is that the answer to this disease is the vaccine. Micronutrient supplements will not offset the lack of vaccination or make you not need the vaccine."

    Researchers caution that the study shouldn't be interpreted as saying vitamin and mineral supplements are bad or should be avoided, but rather make it clear that they are not effective at preventing COVID-19 deaths.

    Beran and Assaly say it's possible that some COVID-19 patients who are malnourished or otherwise deficient in micronutrients may benefit from taking supplements, but that's because their bodies already lack essential nutrients -- not because vitamin D or vitamin C are effective against the virus.

    "What we're saying is this: If you don't medically need these supplements, don't take them thinking they're protective against COVID-19," Beran said. "They're not going to prevent you from getting it and they're not going to prevent you from dying."

  • 原文来源:https://www.sciencedaily.com/releases/2022/02/220217122358.htm
相关报告
  • 《NEJM,6月17日,Genomewide Association Study of Severe Covid-19 with Respiratory Failure》

    • 来源专题:COVID-19科研动态监测
    • 编译者:xuwenwhlib
    • 发布时间:2020-06-19
    • Genomewide Association Study of Severe Covid-19 with Respiratory Failure List of authors. David Ellinghaus, Ph.D., Frauke Degenhardt, M.Sc., Luis Bujanda, M.D., Ph.D., Maria Buti, M.D., Ph.D., Agustín Albillos, M.D., Ph.D., Pietro Invernizzi, M.D., Ph.D., Javier Fernández, M.D., Ph.D., Daniele Prati, M.D., Guido Baselli, Ph.D., Rosanna Asselta, Ph.D., Marit M. Grimsrud, M.D., Chiara Milani, Ph.D., et al., for The Severe Covid-19 GWAS Group* June 17, 2020 DOI: 10.1056/NEJMoa2020283 Abstract BACKGROUND There is considerable variation in disease behavior among patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19). Genomewide association analysis may allow for the identification of potential genetic factors involved in the development of Covid-19. METHODS We conducted a genomewide association study involving 1980 patients with Covid-19 and severe disease (defined as respiratory failure) at seven hospitals in the Italian and Spanish epicenters of the SARS-CoV-2 pandemic in Europe. After quality control and the exclusion of population outliers, 835 patients and 1255 control participants from Italy and 775 patients and 950 control participants from Spain were included in the final analysis. In total, we analyzed 8,582,968 single-nucleotide polymorphisms and conducted a meta-analysis of the two case–control panels. RESULTS We detected cross-replicating associations with rs11385942 at locus 3p21.31 and with rs657152 at locus 9q34.2, which were significant at the genomewide level (P<5×10−8) in the meta-analysis of the two case–control panels (odds ratio, 1.77; 95% confidence interval [CI], 1.48 to 2.11; P=1.15×10−10; and odds ratio, 1.32; 95% CI, 1.20 to 1.47; P=4.95×10−8, respectively). At locus 3p21.31, the association signal spanned the genes SLC6A20, LZTFL1, CCR9, FYCO1, CXCR6 and XCR1. The association signal at locus 9q34.2 coincided with the ABO blood group locus; in this cohort, a blood-group–specific analysis showed a higher risk in blood group A than in other blood groups (odds ratio, 1.45; 95% CI, 1.20 to 1.75; P=1.48×10−4) and a protective effect in blood group O as compared with other blood groups (odds ratio, 0.65; 95% CI, 0.53 to 0.79; P=1.06×10−5). CONCLUSIONS We identified a 3p21.31 gene cluster as a genetic susceptibility locus in patients with Covid-19 with respiratory failure and confirmed a potential involvement of the ABO blood-group system. (Funded by Stein Erik Hagen and others.)
  • 《MedRxiv,2月17日,The Efficacy of Contact Tracing for the Containment of the 2019 Novel Coronavirus (COVID-19)》

    • 来源专题:COVID-19科研动态监测
    • 编译者:dingxq
    • 发布时间:2020-02-18
    • The Efficacy of Contact Tracing for the Containment of the 2019 Novel Coronavirus (COVID-19) Matt J Keeling, T. Deirdre Hollingsworth, Jonathan M Read doi: https://doi.org/10.1101/2020.02.14.20023036 Abstract Contact tracing is a central public health response to infectious disease outbreaks, especially in the early stages of an outbreak when specific treatments are limited. Importation of novel Coronavirus (COVID-19) from China and elsewhere into the United Kingdom highlights the need to understand the impact of contact tracing as a control measure. Using detailed survey information on social encounters coupled to predictive models, we investigate the likely efficacy of the current UK definition of a close contact (within 2 meters for 15 minutes or more) and the distribution of secondary cases that may go untraced. Taking recent estimates for COVID-19 transmission, we show that less than 1 in 5 cases will generate any subsequent untraced cases, although this comes at a high logistical burden with an average of 36.1 individuals (95th percentiles 0-182) traced per case. Changes to the definition of a close contact can reduce this burden, but with increased risk of untraced cases; we estimate that any definition where close contact requires more than 4 hours of contact is likely to lead to uncontrolled spread. *注,本文为预印本论文手稿,是未经同行评审的初步报告,其观点仅供科研同行交流,并不是结论性内容,请使用者谨慎使用.